Q&A Genmab 2020-02-26

	26/2 14:44 af Jan Van de Winkel	Yes the list price was increased by 4.9% in end of January.
	26/2 14:44 af E L	I noted a big increase in the anticipated patient enrollment number for GEN1029 (HexaBody-DR5/DR5) –from 188 to 520- in clinicaltrials.gov. Could you confirm this and would it then be fair to assume this trial is going really well…?
	26/2 14:45 af Jan Van de Winkel	Well the trial is in active recruitment mode and clinical data is anticipated for H2 2020.
	26/2 14:46 af Raffles	Concrats with the 2019 results and thanks for spending time with us. In relation to the Lundbeck study (Lu AF82422 – Parkinson) – this study had primary completion in January 2020 with study completion in June 2020. Do you expect the results from the phase 1-study to be published in the near future? Do you have any expectations to the results and further development and is there any dialogue between Lundbeck and Genmab?
	26/2 14:47 af Jan Van de Winkel	Lundbeck will message progress of this clinical program.
	26/2 14:47 af Bulder	Do you know if Janssen has submitted a placeholder for Andromeda as late breaker at ASCO?
	26/2 14:48 af Jan Van de Winkel	No comment.
	26/2 14:48 af Raffles	If, or when, it eventually comes to the approval process of Epcoritamab do you see any chances of a Priority Review from FDA or would you consider buying a PR-voucher in order to shorten the approval process and thereby catch up with the competing products?
	26/2 14:49 af Jan Van de Winkel	It is too early to detail strategy for regulatory filings. But we continue highly energized and enthusiastic the rapid progress in the expanding epcoritamab clinical program.
	26/2 14:50 af Sukkeralf	Halozymes mentioned that Janssen has selected the ENHANCE technology for JNJ61186372 in december. 2019. Do you consider that a setback (IV not good enough) or further validation of Janssens interest in JNJ61186372?
	26/2 14:52 af Jan Van de Winkel	We see rapid progress in the 372 clinical development and are enthusiastic about a potential subQ formulation to create an even more viable product candidate.
	26/2 14:52 af Sukkeralf	Will there be any daratumumab maintenance readout i 2020?
	26/2 14:53 af Jan Van de Winkel	We have not flagged up a maintenance data readout for 2020
	26/2 14:53 af Jan Van de Winkel	.
	26/2 14:53 af Sukkeralf	Jan how do you see Genmabs future in the ADC space - are you considering newer linker and payloads technologies or something like site specific conjugation?
	26/2 14:54 af Jan Van de Winkel	Our scientists are continuously exploring novel and better ways for ADC approaches.
	26/2 14:55 af Solsen	Mr Winkel Thanks for one more good year ! GEN1046 is one of the “winners” Could you tell us what you have seen since you are so optimistic. And when could it potentially hit the market.
	26/2 14:56 af Jan Van de Winkel	We are very excited about the preclinical validation and the early clinical data in solid cancers...
	26/2 14:57 af Jan Van de Winkel	and especially early signs of clinical activity with patients that do not respond to check point inhibitors.
	26/2 14:57 af Solsen	Mr Winkel How do you see Takedas new products in development in the anti-CD38 landscape. And do Genmab pursue solid tumours in their first hexa-cd38 trials.
	26/2 14:58 af Jan Van de Winkel	We feel that HexaBody CD38 is one of the most exciting molecules in development for treatment of MM...
	26/2 14:58 af Akshay1976	What is the value proposition for Dara SC? Will it be economically beneficial to patients? Or looking at just the convenience of patients? It would be great if we can get answer from both US and EU persepective?
	26/2 14:59 af Jan Van de Winkel	initially we will test it in MM and DLBCL.
	26/2 14:59 af Jan Van de Winkel	Dara subQ will be an advantage for patients and doctors...

	26/2 15:00 af Jan Van de Winkel	recent surveys show high levels of enthusiasm in both the US and the EU.
	26/2 15:01 af chaitea	Which lines of treatment do you anticipate SC dara being used upon approval? Can it be used in newly diagnosed?
	26/2 15:02 af Jan Van de Winkel	We anticipate a broad label based on the submissions by Janssen of the COLUMBA and PLEIADES data.
	26/2 15:03 af Helge Larsen/PI-redaktør	Jan and Andrew. This was all we had for you this time. Thank you for joining us and thank you for the many fulfilling answers to the broad range of interested questions from our investors here at ProInvestor. com. We look very much forward to having you back again here for a Q&A in the near future after Q1.
	26/2 15:04 af Jan Van de Winkel	We have truly enjoyed the interaction and can not wait to chat again. Have a nice day.
	26/2 15:05 af Helge Larsen/PI-redaktør	This session have ended